Brosof A B, Spitzer T Q
Clin Ther. 1980;3(1):3-8.
In this double-blind, randomized, multicenter trial, an oral dosing regimen of 500 mg twice daily (BID) of cephradine was evaluated for the treatment of acute uncomplicated urinary tract infections due to susceptible pathogens. This dose was compared to the already established cephradine regimen of 1,000 mg BID. Of the 218 cases entered into the study, 130 were evaluable for efficacy, 64 in the 500-mg BID group and 66 in the 1,000-mg BID group. There was no statistically significant difference between the two dosage regimens regarding rapidity of clinical improvement, eradication of the pathogens, and overall therapeutic outcome. Successful responses were obtained in 89.1% of the 500-mg BID cases and in 87.9% of the 1,000-mg BID cases. These results demonstrate the safety and efficacy of a 500-mg BID dosing regimen of cephradine for this use. This regimen offers the advantages of convenience, potentially improved compliance, and cost economy.
在这项双盲、随机、多中心试验中，评估了头孢拉定每日两次、每次500毫克（bid）的口服给药方案用于治疗由易感病原体引起的急性单纯性尿路感染。该剂量与已确立的头孢拉定每日两次、每次1000毫克（bid）的方案进行了比较。在纳入研究的218例病例中，130例可进行疗效评估，500毫克bid组64例，1000毫克bid组66例。在临床改善速度、病原体清除和总体治疗结果方面，两种给药方案之间无统计学显著差异。500毫克bid组89.1%的病例和1000毫克bid组87.9%的病例获得了成功应答。这些结果证明了头孢拉定每日两次、每次500毫克给药方案用于此用途的安全性和有效性。该方案具有方便、可能提高依从性和成本经济的优点。
